Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
OSA
Interventions
Atomoxetine 80 mg plus Oxybutynin 5 mg, Atomoxetine 80 MG, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obstructive Sleep Apnea, Down Syndrome
Interventions
Atomoxetine and Oxybutynin (ato-oxy)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Obstructive Sleep Apnea
Interventions
Atomoxetine, Oxybutynin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Conditions
Healthy
Interventions
Oxybutynin Chloride Extended-Release Tablets, 15 mg, Ditropan XL® Extended-release tablets, 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Healthy
Interventions
Oxybutynin Chloride Extended-release Tablets 5 mg, Ditropan XL® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Urinary Incontinence, Urge
Interventions
oxybutynin
Drug
Lead sponsor
FemmePharma Global Healthcare, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Hackensack, New Jersey
Completed Phase 3 Interventional Results available

Behavioral Treatment of Overactive Bladder in Men

NCT01187498
Conditions
Overactive Bladder
Interventions
Behavioral training, Oxybutynin chloride, extended-release
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • Decatur, Georgia
Conditions
Obstructive Sleep Apnea (OSA), Down Syndrome
Interventions
ato-oxy, Oxygen
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Miami, Florida + 2 more
Conditions
Overactive Bladder
Interventions
trospium chloride, oxybutynin IR, oxybutynin IR placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Hot Flashes
Interventions
Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Conditions
Sleep Apnea
Interventions
Atomoxetine, Oxybutynin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Oxybutynin Topical Gel on Gastric Emptying

NCT00926926
Conditions
Healthy
Interventions
Oxybutynin Chloride Gel, Placebo Gel
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Saint Charles, Missouri
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products

NCT03205605
Conditions
Heat Effect
Interventions
oxybutynin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Diabetic; Neuropathic, Polyneuropathy (Manifestation)
Interventions
3% oxybutynin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions
Oxybutynin Chloride IR, Mirabegron
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Completed Phase 4 Interventional Accepts healthy volunteers

Effects Of Detrol LA On Memory And Cognition In Elderly Population

NCT00411437
Conditions
Memory, Cognition
Interventions
Tolterodine ER, Oxybutynin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
65 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more
Conditions
Overactive Detrusor, Neurogenic Bladder
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Loma Linda, California • Orange, California • Aurora, Colorado + 7 more